SCANDION ONCOLOGY A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.89 SEK | -25.21% |
|
-36.65% | -77.72% |
| May. 15 | Transcript : Scandion Oncology A/S - Special Call | |
| Mar. 21 | Scandion Oncology Reports Updated Phase II Corist Data, Including Topline Overall Survival | CI |
| Sales 2022 | - | Sales 2023 | - | Capitalization | 109M 1.16B |
|---|---|---|---|---|---|
| Net income 2022 | -76M -810M | Net income 2023 | -39M -416M | EV / Sales 2022 | - |
| Net cash position 2022 | 76.01M 810M | Net cash position 2023 | 26.02M 277M | EV / Sales 2023 | - |
| P/E ratio 2022 |
-0.99
x | P/E ratio 2023 |
-2.78
x | Employees | 4 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 94.68% |
More Fundamentals
* Assessed data
More news
Latest transcript on Scandion Oncology A/S
More press releases
| 1 day | -25.21% | ||
| 1 week | -36.65% | ||
| Current month | -33.83% | ||
| 1 month | -38.62% | ||
| 3 months | -66.60% | ||
| 6 months | -51.79% | ||
| Current year | -77.72% |
1 week
0.80
1.40
1 month
0.801.56
Current year
0.805.64
1 year
0.805.64
3 years
0.8021.75
5 years
0.8075.00
10 years
0.8075.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jan Stenvang
FOU | Founder | - | 16-12-31 |
| Chief Executive Officer | 64 | 23-01-01 | |
Johnny Stilou
DFI | Director of Finance/CFO | 57 | 21-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 22-03-31 | |
| Director/Board Member | 69 | 18-05-06 | |
Martin Møller
CHM | Chairman | 49 | 21-04-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 0.89 | -25.21% | 1,012,765 |
| 24-05-23 | 1.19 | -4.03% | 209,221 |
| 24-05-22 | 1.24 | +4.64% | 214,123 |
| 24-05-21 | 1.185 | -2.87% | 200,169 |
| 24-05-20 | 1.22 | -13.17% | 220,401 |
Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:29 am EDT
More quotes
Scandion Oncology A/S is a manufacturer of biological products. The Company was founded in May 2017 and is located in Copenhagen, Denmark. It focuses on modern onclogy, the treatment of cancers that have developed resistance to chemotherapy.
Calendar
May. 22
- Q1 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -77.72% | 3.4M | |
| +12.30% | 118B | |
| +12.15% | 106B | |
| -8.14% | 23.4B | |
| -1.69% | 21.78B | |
| -10.60% | 18.09B | |
| -41.25% | 16.72B | |
| -15.33% | 15.97B | |
| +5.80% | 14.03B | |
| +28.03% | 11.67B |
- Stock Market
- Equities
- SCOL Stock
